ReviewBritish journal of clinical pharmacology2019

Regulatory aspects of the development of drugs for metabolic bone diseases - FDA and EMA perspective.

Theresa Kehoe et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.